Monographie - Filgrastim - Stabilis 4.0

Ultimele actualizari :
19/11/2024

Diverse

Filgrastim

Injectabil

Stabilitatea in solutie

Stabilitatea in amestec

Factorii care influenteaza stabilitatea

Compatibilitate

Microunde

Bibliografie

pdf

Denumirea comerciala

Denumirea comerciala

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Accofil	Belgia, Germania, Marea Britanie
Biocilin	Mexic
Duperan	Chilli
Filgen	Argentina
Foltran	Chilli
Granulokine	Grecia, Italia
Hebervital	Columbia
Inmunef	Columbia
Leucosos	Columbia
Lioplim	Chilli
Neupogen	Africa de Sud, Austria, Belgia, Croatia, Danemarca, Elvetia, Finlanda, Franta, Marea Britanie, Olanda, Polonia, Portugalia, Slovenia, Spania, SUA, Suedia, Turcia
Neutromax	Argentina
Neutropine	Argentina
Nivestim	Belgia, Franta, Germania, Marea Britanie, Norvegia, Olanda
Ratiograstim	Austria, Germania, Marea Britanie, Suedia
Tevagrastim	Elvetia, Germania, Marea Britanie, Norvegia, Olanda, Suedia

Bibliografie

Injectabil

Bibliografie : Filgrastim

	tip	publicare
99	ziar	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
104	ziar	Hall PD, Yui D, Lyons S, Bosso JA. Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 185-189.
182	ziar	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	ziar	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
2269	ziar	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3128	Laborator	Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013
3249	ziar	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3256	ziar	Burnett B, Radic I. Stability of Hospira filgrastim following changes to thermal and photic storage conditions. EJHP 2011 ; 17, 5: 49-56.
3474	Laborator	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3618	Laborator	Filgrastim (Neupogen®) - Summary of Product Characteristics Amgen 2014
3828	poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
4055	ziar	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4380	Laborator	Posaconazole (Noxafil®) - Summary of Product Characteristics Merck Sharp & Dohme Limited 2019
4471	Laborator	Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019 Kyowa Kirin Pharma 2019
4521	ziar	Polo C, D’Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B. Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit. Pharmaceutical Technology in Hospital Pharmacy 2020
4650	Laborator	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021

Mentions Légales